Mkt Cap $33B
52wk $34.00 - $156.25
10d ago
≠
We disagree with Wall Street.
Analyst consensus: bullish. Our position: bearish.
See factor model below for why.
Insider selling: $480,611 sold by 1 insider (30d)
Factor divergence:
DIVERGENCE: insider_activity, price_momentum, narrative_gap bullish vs estimate_revisions, analyst_r
Est. revisions:
-3.7%
Backed by structured data (insider trades, analyst ratings, or filings)
Factor Model (net -0.4)
Factor Model
net -0.4 2.7 / 10
Est. Revisions
-0.2
Insider Activity
+0.5
Momentum
+0.8
Analyst Rev.
-1.0
Narrative Gap
+0.5
Needham Maintains Buy Despite Wider Loss
Watch: Watch RASolute 301 study progress as completion timing remains key to near-term catalysts.
Revolution Medicines missed Q1 2026 EPS estimates with a loss of $2.29 versus the $1.64 consensus. Marketing and R&D expenses totaled $113.7M, up $8M in stock-based costs, driving a full-year expense projection increase to $260-280M. The RASolute 301 study enrollment rose to 590 patients, expected to complete mostly in 2026.
This widened loss and higher expense projection highlight cost pressures but keep momentum in clinical development, critical for advancing pipeline value and future approvals.
Evidence
9d ago
Bernstein init RVMD: Market Perform
19d ago
Revolution Medicines (RVMD) Receives FDA’s “Safe to Proceed” Letter for Daraxonrasib
yahoo-finance
23d ago
RBC Capital main RVMD: Outperform → Outperform
23d ago
Wedbush main RVMD: Outperform → Outperform
23d ago
Piper Sandler main RVMD: Overweight → Overweight
24d ago
Needham main RVMD: Buy → Buy
7 older signals
38d ago
Leerink Partners main RVMD: Outperform → Outperform
39d ago
HC Wainwright & Co. reit RVMD: Buy → Buy
41d ago
Insider sell by GOLDSMITH MARK A (RVMD): $18,010,488
41d ago
Stifel reit RVMD: Buy → Buy
41d ago
Needham main RVMD: Buy → Buy
Fundamentals & Data ▾
Revolution Medicines, Inc.
Healthcare · Biotechnology
Mkt Cap
$33B
Beta
1.41
52w Range
$34.00 - $156.25
Short Interest
12.8M 6.36%
Days to Cover
3.1 -17%
Technicals
mixed
vs 20d MA
+6.0%
from 52w Hi
0.0%
Vol (20d)
40%
1w return
+2.4%
1m return
+12.1%
Vol ratio
1.3x
Insiders
selling
0B / 6S
Analysts
bullish
1 up / 0 down
EPS Estimate
$-2.00
-3.7% 30d
0up / 13dn
Est. Dispersion
34%
18 analysts
Analyst Target
$183
$151 - $263
Options P/C
0.85
Fund Convergence
strong
D.E. Shaw, Citadel, Two Sigma, Renaissance
Top Holders
D.E. Shaw
$557M
Citadel
$115M
Two Sigma
$23M
Renaissance
Recent Filings & Data
insider trade
2
net selling
· $480,611 sold
1 insider · 2 transactions (30d)
Recent transactions
MANCINI ANTHONY · sell · $480,611
MANCINI ANTHONY · exercise · $104,928
analyst rating
1
Bernstein
init
→ Market Perform
9d ago
Track Record (1/2 correct) ▾
Direction History
1/2 correct at 5 days
2026-05-21
bearish
+2.4%
✗
2026-04-14
bullish
+1.3%
✓
15 signals · latest 9d ago
Keep reading the market
Direction shifts, insider clusters, filing red flags, and earnings call changes stay published on the site.